Acute renal failure (ARF) is a serious medical complication characterized by an abrupt and sustained decline in renal function. Despite significant advances in supportive care there is currently no effective treatment to restore renal function. Prostaglandin E 2 (PGE 2 ) is a lipid hormone mediator abundantly produced in the kidney where it acts locally to regulate renal 
Introduction
Acute renal failure (ARF) is characterized by an abrupt and sustained decline in the glomerular filtration rate (46) . Despite significant advances in supportive therapy over the last few decades, ARF remains a serious medical condition associated with high levels of morbidity and mortality (7, 18) . Depending on the definition used, ARF has been reported to affect from 1% to 25% of patients admitted to intensive care units and has led to mortality rates from 15% to 60% (17) . Based on the progress made in understanding the pathophysiology of ARF, many therapeutic agents have been developed and tested in animal models of ARF (24) . However, only limited success has been achieved in human clinical trials with pharmacological agents such as loop diuretics, mannitol, dopamine receptor agonists, atrial natriuretic peptide, adenosine antagonists, N-acetylcysteine, insulin-like growth factor-1 and calcium entry blockers (24, 46) . The lack of effective treatments for ARF warrants the identification of new molecular targets and approaches to develop efficient therapeutic agents for the treatment of renal insufficiency.
Prostaglandins which are derivatives of the cyclooxygenase-catalyzed conversion of arachidonic acid are potent mediators of renal function and hemodynamics (3, 8) . PGE 2 is one of the major prostanoids found in the kidney and it exerts its biological actions through one of the four EP receptors, EP 1 -EP 4 . The EP 4 receptors are predominantly expressed in the glomerulus and in preglomerular vessels, but they are also expressed in the distal convoluted tubule, cortical collecting duct and outer medullary vasa recta (4, 16) . Activation of EP 4 by PGE 2 has a vasodilatory effect on renal vascular tone (41) , stimulates renin release in juxtaglomerular cells (10) and promotes cell survival of podocytes (1) . An EP 4 -specific orthosteric (natural ligand binding site) agonist was found to reduce nephrotoxic injury and increased the survival rate of rats with mercury chloride-induced ARF (49), and an EP 4 agonist prevented the development of glomerulonephritis (34) . These studies suggest that modulating EP 4 receptor activity could improve renal function in ARF.
In contrast to orthosteric ligands, functionally selective allosteric modulators of G protein-coupled receptors (GPCRs) offer advantages by exerting effects on some (desirable) receptor-mediated pathways without interfering with other pathways which are best left intact (12, 13, 19, 25, 45) ; hence, orthosteric ligands exhibit undesirable properties by lacking selectivity. There is increasing evidence that peptides derived from various extracellular and juxtamembranous regions of GPCRs can interfere with their respective activities, as demonstrated for example for the prostaglandin F 2α (13, 38) , vasopressin type 2 (40) and ß 2 adrenergic (14) receptors. Peptides that target regions of the receptor remote from the (natural ligand) orthosteric -binding site often exhibit non-competitive allosteric properties and modulate only a subset of the receptor-mediated activities, allowing more specific pharmacological intervention targeting some, but not all receptor signaling pathways. This concept, referred to as functional selectivity, has been described for numerous compounds (12, 45) including non-competitive antagonists (19, 25) .
The aim of the present work is to study the efficacy of a new (d-) peptidomimetic EP 4 receptor modulator in tempering ARF; in this process we investigated its mode of action. We hereby describe that the optimized peptidomimetic THG213.29, which possesses functional selectivity towards the EP 4 receptor, proved to be efficacious in improving renal function and structural outcome in ischemia-and nephrotoxin-induced rat models of ARF.
Material and Methods
Animals and reagents -Animals were used according to a protocol of the Ste-Justine Hospital Animal Care committee and along the principles of the Guide for the Care and Use of Experimental Animals of the Canadian Council on Animal Care. THG213.29 was a kind gift from Theratechnologies (Montreal, QC, Canada); peptides were synthesized using F-moc chemistry and the solid phase Merrifield method, and peptide purity was assessed by HPLC and mass spectrometry. PGE 2 , U-46619 and GW627368X were purchased from Cayman Chemical (Ann Arbor, MI). L-902688(51) was a kind gift from Merck Frosst (Kirkland, QC, Canada). All other chemicals were purchased from Sigma-Aldrich (Oakville, ON, Canada).
Vascular ring preparation -Newborn piglets (1-4 days old) were anesthetized with halothane (1.5%) and the lower external saphenous veins removed and placed in cold Krebs buffer (120 mM NaCl, 4.5 mM KCl, 2.5 mM CaCl2, 1 mM MgSO4, 27 mM NaHCO3, 1 mM KH2PO4, 10 mM glucose, pH 7.4) to which 1.5 U/ml heparin was added. The veins were cleaned of extraneous tissue and cut in 3-4 mm rings which were placed in individual jacketed 15 ml organ baths containing Krebs buffer saturated with 95% O 2 /5% CO 2 and maintained at 37°C. The rings were equilibrated for 60 minutes under 2 g tension and were pre-treated or not with THG213.29 for 30 min prior to addition of U-46619 (0.2 µM). When the response to U-46619 reached a steady state, PGE 2 or L-902688 was added. Tension was measured by force-displacement transducers and was recorded using Work Bench software (Kent Scientific, Litchfield, CT).
Renal function -All experimental procedures were performed under anesthesia. Male Sprague-Dawley adult rats (250-300 g) were anesthetized using 100 mg/kg of ketamine/xylazine (9:1, w:w) injected intra-peritoneally (i.p.), female Beagle dogs were anesthetized with an i.v. injection of thiopental (5 mg/kg) and the anesthesia continued under isoflurane, while juvenile pigs (6-10 kg) were anesthetized with 1.5% halothane. The animals were kept warm and their body temperature monitored every 15 minutes. Renal function were determined as previously described (36) . Briefly, the carotid artery was cannulated to measure the arterial blood pressure with a pressure transducer (Gould Easy Graph) and to collect blood samples. A catheter was inserted at the tip of the bladder to collect urine. The jugular (rats), cephalic (dogs) or femoral (pigs) vein was also catheterized for infusion of saline containing the anesthetics and [ vein. Urine and blood samples were then collected every 20 minutes for an additional period of 2 h. The radioactivity in the blood and urine samples was measured with a liquid scintillation counter. Urine flow rates, GFR and RPF were determined at different times and averaged for a 60 min period starting 20 min after drug administration. Urinary volume (UV) was calculated and expressed as μl of urine/min corrected for the weight of the animal. GFR and RPF were calculated as the ratio of urinary [ for the volume of the urine and the weight of the animal. Intrafemoral arterial blood pressure was also measured. Moreover, blood urea nitrogen and serum creatinine levels were measured using QuantiChrom assay kits (BioAssay Systems, Hayward, CA).
Cisplatin-induced model of acute renal failure -ARF and tubular necrosis was induced by i.p. injection of 17.5 mg/kg of cisplatin to Sprague-Dawley male rats on day 1. Rats were treated (i.v.) with saline or THG213.29, either 1 mg/kg on day 5 or 5 mg/kg three times a day from days 2 to 5. Renal function was then assessed on day 5, as described above.
Ischemic renal artery occlusion model of acute renal failure -Male Sprague-Dawley rats were cannulated and basal GFR determined as described above. The left and right renal arteries were then clamped for a period of 60 minutes to induce acute renal ischemia.
Following the ischemic period, clamps were removed and the animals were immediately treated with THG213.29 (1 mg/kg i.v. bolus), fenoldopam (0.6 µg/kg bolus dose, followed by 0.6 µg/kg/h) or saline via the jugular vein. Sham-operated rats underwent the same procedure without renal artery clamping. At the end of their assigned period, the animals were either sacrificed to obtain tissue samples or anesthetized to measure renal parameters as described above.
Histology -Kidneys were fixed in 10% formalin, paraffin-embedded and the specimens stained with periodic acid-Schiff stain. Histological changes were evaluated by quantitative measurements of glomerular structural changes, as well as obstruction of collecting ducts and tubules -performed in a blinded manner relative to treatment assignment (by XH and DRV). Statistical analysis -Values are presented as mean ± S.E.M. Curve-fitting and statistical analysis was conducted by using GraphPad Prism 4 software. Statistical difference between two groups was measured using Student's t-test, and for differences between more than two groups by one-way ANOVA followed by Dunnett's post-test. For comparison between treatments and cell line for gene expression levels, two-way ANOVA followed by
Bonferroni's post-test was used. Statistical significance was set at P <0.05.
Results

THG213.29 is derived from an EP 4 extracellular juxtamembranous region and acts via EP 4
Initially, the all d-peptide THG213 (iftsyecl; Fig. 1b ) was derived from the first extracellular loop and transmembrane-3 junction of the human EP 4 receptor (Fig. 1a) , as reported for other GPCRs (13, 38) (40). In the process of optimizing THG213 for efficacy (and solubility), derivatives were generated and tested for their ability to modulate PGE 2 -induced vasodilation of piglet saphenous veins; this complex multi-signal-dependent physiological functional assay was deliberately used to avoid a screening bias towards classical but potentially nonrelevant signaling pathways, and because PGE 2 -induced vasorelaxation of porcine saphenous vein is foremost EP 4 -dependent (50), whereas stimulation of EP 2 and to an even lesser extent of EP 3 hardly relaxes saphenous veins (27, 33) . Relevantly in the present context, we also (Fig. 2D ). The potency of THG213.29 to inhibit EP 4 -mediated cAMP production was low (pIC 50 of 5.52 ± 0.68; Fig. 2E ) but specific, as neither inhibition of PGE 2 -mediated cAMP production was observed in HEK293E cells transfected with the closely related prostaglandin EP 2 receptor, nor of (unrelated) AVP-mediated cAMP production by the vasopressin 2 receptor (Fig. 2F) GFR essentially doubled with a maximal effect found at a dose of 2 mg/kg in rats and pigs and at 5 mg/kg in dogs (Fig. 3A) . Renal plasma flow and urine output were also augmented by THG213.29 administration in normal dogs and pigs, with a borderline increase for renal plasma flow in rats, (Fig. 3B, C) ; mean arterial blood pressure remained stable after injection of THG213.29 as shown on representative averaged tracing of blood pressure in dogs (Fig.   3D ), and on compiled data in rats, dogs and pigs ( Fig. 3E-G) . Thus, effects of THG213.29 on renal functional parameters tested were species-independent.
Efficacy of THG213.29 in a cisplatin-induced nephrotoxic acute renal failure rat model
Nephrotoxic effects resulting from the use of antineoplastic, radiocontrast and antimicrobial agents can result in ARF (35) . Cisplatin is a common and effective chemotherapeutic agent used for the treatment of various malignancies with unfortunate dose-limiting nephrotoxicity observed in 25-35% of treated patients (39) . We tested the efficacy of THG213.29 in a cisplatin-induced nephrotoxicity rat model of acute tubular necrosis and renal failure. Five days after administration of cisplatin to Sprague-Dawley rats there was a dramatic decline in GFR, renal plasma flow and urine output (Fig. 4A) , and consequently a progressive increase of serum blood urea nitrogen (BUN) and creatinine levels ( 
Effects of THG213.29 on EP 4 -dependent gene expression
In an attempt to understand the effects of THG213.29 in renal function and structure in ARF Extracellular loops and the extracellular portions of transmembrane helices play an important role in the overall pharmacology of GPCRs (6), and there is a conformational coupling between the extracellular surface and the orthosteric binding site (2). THG213.29
was derived from a juxtamembranous region of the EP 4 receptor that is distinct from the presumed orthosteric binding site, which is located in the case of the closely related prostacyclin receptor mostly within the transmembrane core (42) . Consequently, THG213.29 exhibited non-competitive properties towards EP 4 as it did not displace bound PGE 2 but modulated PGE 2 binding dissociation kinetics (Fig. 2 B, C) . The non-competitive nature of THG213.29 is corroborated by the inability of high concentrations of PGE 2 to overcome the partial inhibitory effects of THG213.29 on PGE 2 -induced cAMP production (insurmountable antagonism) (Fig. 2 D,E Fig. 2A (ii)) ; ii) attenuated cAMP response in EP 4 but not EP 2 or V2R-expressing HEK293 cells ( Fig 2F) ; iii) modulated PGE 2 binding dissociation kinetics to the EP 4 receptor (Fig. 2C) ; and iv) modulated the L-902688-induced increased expression of various mRNAs in EP 4 -expressing cells only (Fig. 6B ).
In the past several years, it has become increasingly clear that G protein-coupled receptors can activate independently a variety of signaling effectors, and that the ability of a compound to modulate a given signaling pathway cannot be extrapolated to another signaling pathway triggered by the same receptor. The conceptual basis for this is that GPCRs do not have merely "inactive" and "active" conformations, but that ligands can stabilize distinct receptor conformations, which are more or less potent and efficient in activating a given readout (21) . This infers that a drug can affect some, but not all, functions evoked by a receptor, a concept referred to as functional selectivity (45). The difficulty to accommodate functional selectivity in screening campaigns has been pointed out (22) ; hence, a complex isolated-tissue physiological functional assay (piglet saphenous vein vasorelaxation) was initially used to determine the efficacy of peptides to avoid overseeing signaling responses based on reductionist in vitro recombinant systems. THG213.29 inhibited both PGE 2 and L-902688-mediated vasorelaxation in this system. In an effort to decipher the effect of THG213.29 on EP 4 activities, we investigated more specific signaling pathways using BRET-based assays in living HEK293 cells. EP 4 -mediated cAMP production was partially but specifically inhibited by THG213.29, while the Gα i1 activation and β-arrestin recruitment pathways activated by PGE 2 were unaffected by THG213.29 ( Fig. 2F-H from 106 normal untreated rats or 4-6 rats per treatment group, *P <0.05, **P <0.01 compared to cisplatin protocol rats treated with saline; (B) BUN and serum creatinine were measured in saline-treated rats daily for five days after administration of cisplatin; (C) animals were injected with cisplatin on day 1, treated with saline or THG213.29 three times a day (5 mg/kg i.v.) from days 2 to 5 after cisplatin, and BUN and serum creatinine were measured on day 6 (n = 4); data represent mean ± S.E.M. *P <0.05 compared to salinetreated rats (ANOVA followed by trend analysis); (D) hypertrophic glomeruli and/or erythrocyte extravasation and collecting duct obstruction were quantified from histology kidney sections of cisplatin-injected rats collected 72 h after treatment with saline or THG213.29 (5 mg/kg i.p., three times a day from days 2 to 5 after cisplatin). Data represent mean ± S.E.M. from 2 rats per treatment group, **P <0.01 compared to saline-treated rats; (E) kidney sections from normal (control) or cisplatin-injected rats collected 72 h after treatment with saline or THG213.29 (5 mg/kg i.p., three times a day from days 2 to 5 after cisplatin). S.E.M. of 3 experiments, each performed in triplicate; *P <0.05, **P <0.01, ***P <0.001.
